Answers are grounded in this paper and cite their sources.
Clinically significant oral mucositis (OM) is a frequently reported toxicity of TROP-2 directed ADCs containing a topoisomerase inhibitor payload, such as datapotamab deruxtecan (Dato-DXd). It seems likely that the mechanism underlying this important toxicity is consistent with the established biological cascade associated with other cytotoxic regimens and a consequence of the expression of TROP-2 on normal oral mucosa. Since it is probable that the biological processes underlying TROP-2 ADC induced OM are distinct from the inflammatory pathogenesis of stomatitis caused by mTOR inhibitors (mIAS), a rational interventional strategy which recognizes these different biological targets is critical for developing effective prevention and treatment.
No takes yet. Share an insight, caveat, or question.
Sonis et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: